Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Smart pillow ODM manufacturer Vietnam

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Indonesia graphene sports insole ODM

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Breathable insole ODM development Thailand

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Eco-friendly pillow OEM manufacturer China

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Pillow ODM design and manufacturing company in Taiwan

CRISPR illustration. Credit: National Institutes of Health A compact and efficient CRISPR-Cas system, named CasMINI, could be broadly useful for cell-engineering and gene-therapy applications because it is easier to deliver into cells. The findings appear in a study that was published on September 3, 2021, in the journal Molecular Cell. “This is a critical step forward for CRISPR genome-engineering applications,” says senior study author Stanley Qi of Stanford University. “The work presents the smallest CRISPR to date, according to our knowledge, as a genome-editing technology. If people sometimes think of Cas9 as molecular scissors, here we created a Swiss knife containing multiple functions. It is not a big one, but a miniature one that is highly portable for easy use.” The development of CRISPR-Cas systems for human cells has revolutionized genome engineering. These systems offer opportunities for the development of gene therapies for a variety of genetic diseases. But their large sizes often restrict delivery into cells and thus impede clinical applications. For example, adeno-associated virus (AAV), a vector widely applied for in vivo delivery, has limited packaging capacity of the payload (less than 4.7 kb), and many Cas fusion proteins are beyond this limit. As a result, there is a need to engineer highly efficient, compact Cas systems to facilitate the next generation of genome-engineering applications. One potential solution is Cas12f, also known as Cas14. Ranging between 400 and 700 amino acids, the protein is less than half the size of currently used CRISPR systems such as Cas9 or Cas12a. But until now, it was not clear whether this compact protein could be used in mammalian cells. “Recent years have identified thousands of CRISPRs, which are known as bacteria’s immunity defense system,” Qi explains. “More than 99.9% of discovered CRISPRs, however, cannot work in human cells, limiting their use as genome-editing technologies.” In the new study, Qi and his team applied RNA and protein engineering to the Cas12f system to generate an efficient miniature Cas system for mammalian genome engineering. Derived from archaea, the natural Cas12f protein and its single-guide RNA showed no detectable activity in mammalian cells. By optimizing the single-guide RNA design and performing multiple rounds of iterative protein engineering and screening, the researchers generated a class of Cas12f variants named CasMINI. The engineered Cas12f protein variants combined with engineered single-guide RNAs exhibited efficient gene-regulation and gene-editing activity. The researchers demonstrated that CasMINI can drive high levels of gene activation comparable to those associated with Cas12a and allows for robust base editing and gene editing. Moreover, it is highly specific and does not produce detectable off-target effects. “Here we turn a non-working CRISPR in mammalian cells, via rational RNA engineering and protein engineering, into a highly efficient working one,” Qi says. “There were previous efforts from others to improve the performance of working CRISPRs. But our work is the first to make a non-working one working. This highlights the power of bioengineering to achieve something evolution has not yet done.” The size of the engineered CasMINI molecule is only 529 amino acids. This small size makes it suitable for a wide range of therapeutic applications. For example, the CasMINI fusion proteins are well suited for AAV packaging. In addition, CasMINI mRNA can be easily packaged into lipid nanoparticles or other RNA-delivery modalities, potentially enhancing its entry into cells. Its small size and non-human pathogen source might make it less likely to produce immune responses than large protein payloads would be. More work is needed to further optimize the efficiency of CasMINI for base editing and gene editing and to test the performance of the system in vivo with different delivery modalities. The researchers plan to test the system for in vivo gene-therapy applications. “The availability of a miniature CasMINI enables new applications, ranging from in vitro applications such as engineering better tumor-killing lymphocytes or reprogramming stem cells to in vivo gene therapy to treat genetic diseases in the eye, muscle, or liver,” Qi says. “It is on our wish list that it will become a therapy to treat genetic diseases, to cure cancer, and to reverse organ degeneration.” For more on this mini CRISPR system, see “Mini” CRISPR Genetic Editing System Engineered. Reference: “Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing” by Xiaoshu Xu, Augustine Chemparathy, Leiping Zeng, Hannah R. Kempton, Stephen Shang, Muneaki Nakamura and Lei S. Qi, 3 September 2021, Molecular Cell. DOI: 10.1016/j.molcel.2021.08.008 This work was supported by the Pew Scholar Foundation, the Alfred P. Sloan Foundation, and the Li Ka Shing Foundation. L.S.Q. is a founder and shareholder of Epicrispr Biotechnologies and Refuge Biotechnologies. L.S.Q. is a member of the scientific advisory board of Epicrispr Biotechnologies and Refuge Biotechnologies. The authors have filed provisional patents via Stanford University related to the work.

New research reveals that learning in the brain occurs not just when there are external rewards like food or money, but also naturally through the constant ebb and flow of dopamine and acetylcholine. The researchers found that this hormonal balancing act is ongoing and independent of rewards, potentially offering new insights into neuropsychiatric conditions. The Findings Could Explain How Memories Form Throughout the Day Scientists have long believed that rewards such as food or money stimulate learning by triggering the release of dopamine, a hormone associated with pleasure and positive reinforcement. However, a recent rodent study suggests that learning can still happen even when there is no immediate reward involved. Conducted by a team from NYU Grossman School of Medicine, the study examined the interaction between dopamine and acetylcholine, another brain chemical involved in learning and memory. Previous studies indicated that these two hormones have an inverse relationship; an increase in one leads to a decrease in the other. It was previously thought that rewards facilitate learning by simultaneously elevating dopamine levels while reducing acetylcholine. Neuroplasticity and Learning Without External Rewards This sudden hormone imbalance is believed to open a window of opportunity for brain cells to adjust to new circumstances and form memories for later use. Known as neuroplasticity, this process is a major feature of learning as well as recovery after injury. However, the question remained whether food and other external rewards are the only drivers for this memory system, or whether our brains instead are able to create the same conditions that are favorable to learning without outside help. To provide some clarity, the study authors focused on when and under what circumstances dopamine levels are high at the same time as acetylcholine levels are low. They found that this situation occurs frequently, even in the absence of rewards. In fact, it turns out that the hormones constantly ebb and flow in the brain, with dopamine levels regularly raised while acetylcholine levels are low, setting the stage for continual learning. “Our findings challenge the current understanding of when and how dopamine and acetylcholine work together in the brain,” said study lead author Anne Krok, PhD. “Rather than creating unique conditions for learning, rewards take advantage of a mechanism that is already in place and is constantly at work,” added Krok, who is also a medical student at NYU Grossman School of Medicine. For the research, which was recently published in the journal Nature, the study team gave dozens of mice access to a wheel on which they could run or rest at will. On occasion, the researchers offered the animals a drink of water. Then they recorded rodent brain activity and measured the amount of dopamine and acetylcholine released at different moments. Natural Brain Rhythms for Learning As expected, the drink treats created the typical patterns of dopamine and acetylcholine release that are prompted by rewards. However, the team also observed that well before receiving water treats, dopamine, and acetylcholine already followed “ebb and flow” cycles approximately twice every second, during which the levels of one hormone dipped while the other surged. Krok notes that this pattern continued regardless of whether the rodents were running or standing still. Similar brain waves have been observed in humans during periods of introspection and rest, she adds. “These results may help explain how the brain learns and rehearses on its own, without the need for external incentives,” said study senior author and neuroscientist Nicolas Tritsch, Ph.D. “Perhaps this pulsing circuit triggers the brain to reflect on past events and to learn from them.” That said, Tritsch, an assistant professor in the Department of Neuroscience and Physiology at NYU Langone Health, cautions that their research was not designed to tell whether mouse brains process information the same way as human brains do during this “self-driven” learning, as he describes it. Potential Implications for Mental Health Disorders Nevertheless, he says, the results of the study may also offer insight into new ways of understanding neuropsychiatric conditions that have been tied to incorrect levels of dopamine, such as schizophrenia, attention-deficit/hyperactivity disorder (ADHD), and depression. In schizophrenia, for example, patients often experience delusions that contradict reality. If the dopamine-acetylcholine circuit is constantly strengthening connections in the brain, says Tritsch, then problems with this mechanism might lead to the formation of too many, and incorrect, connections, causing them to “learn” of events that did not really occur. Similarly, lack of motivation is a common symptom of depression, making it challenging to perform basic tasks such as getting out of bed, brushing teeth, or going to work. It is possible that a disruption in the internal-drive system might be contributing to these issues, the authors say. As a result, Tritsch says the research team next plans to examine how dopamine-acetylcholine cycles behave in animal models of such mental illnesses, as well as during sleep, which is important for memory consolidation. Reference: “Intrinsic dopamine and acetylcholine dynamics in the striatum of mice” by Anne C. Krok, Marta Maltese, Pratik Mistry, Xiaolei Miao, Yulong Li and Nicolas X. Tritsch, 9 August 2023, Nature. DOI: 10.1038/s41586-023-05995-9 Funding for the study was provided by National Institutes of Health grants DP2NS105553, R01MH130658, T32NS086750, T32GM007308, and T32GM136573. Further funding was provided by the Alfred P. Sloan Foundation, the Danna Foundation, the Whitehall Foundation, the Feldstein Medical Foundations, and the Vilcek Scholars Award. In addition to Krok and Tritsch, other investigators involved in the study were Marta Maltese, Ph.D.; Pratik Mistry, MS; at NYU Langone, and Xiaolei Miao, Ph.D.; and Yulong Li, Ph.D., at Peking University School of Life Sciences in Beijing.

Researchers have discovered that oligodendrocytes contribute to amyloid beta production in Alzheimer’s disease, challenging the belief that neurons are the sole source. Targeting these cells may offer a novel method for managing the disease, as reducing their amyloid beta output can improve neuronal function. Credit: SciTechDaily.com A new study from the UK Dementia Research Institute reveals that oligodendrocytes, non-neuronal brain cells, produce amyloid beta, a key protein in Alzheimer’s disease. Researchers demonstrated that suppressing amyloid beta production in these cells in a mouse model can alleviate abnormal neuronal hyperactivity, suggesting a new therapeutic approach to treating Alzheimer’s by targeting oligodendrocytes. Oligodendrocyte Involvement in Alzheimer’s Oligodendrocytes are an important source of amyloid beta (Aβ) and play a key role in promoting neuronal dysfunction in Alzheimer’s disease (AD), according to a study published today (July 23, 2024) in the open-access journal PLOS Biology by Rikesh Rajani and Marc Aurel Busche from the UK Dementia Research Institute at University College London, and colleagues. AD is a devastating neurodegenerative disorder affecting millions of people worldwide. Accumulation of Aβ – peptides consisting of 36 to 43 amino acids – is an early critical hallmark of the disease. Recent clinical trials demonstrating a slowing of cognitive and functional decline in individuals with AD who are treated with anti-Aβ antibodies reinforce the important role of Aβ in the disease process. Despite the key cellular effects of Aβ and its essential role in AD, the traditional assumption that neurons are the primary source of toxic Aβ in the brain has remained untested. Scientist captures images of human oligodendrocytes in a dish (stained green), which produce the protein implicated in causing Alzheimer’s disease. Credit: Francesca Lam (CC-BY 4.0) In the study, Rajani and Busche showed that non-neuronal brain cells called oligodendrocytes produce Aβ. They further demonstrated that selectively suppressing Aβ production in oligodendrocytes in an AD mouse model is sufficient to rescue abnormal neuronal hyperactivity. The results provide evidence for a critical role of oligodendrocyte-derived Aβ for early neuronal dysfunction in AD. Collectively, the findings suggest that targeting oligodendrocyte Aβ production could be a promising therapeutic strategy for treating AD. Implications for Alzheimer’s Treatment According to the authors, the functional rescue is remarkable given the relatively modest reduction in plaque load that results from blocking oligodendrocyte Aβ production, while blocking neuronal Aβ production leads to a near elimination of plaques – another hallmark of the disease. This small contribution of oligodendrocytes to plaque load could suggest that a main effect of oligodendrocyte-derived Aβ is to promote neuronal dysfunction. Together with the data showing an increased number of Aβ-producing oligodendrocytes in deeper cortical layers of the brains of individuals with AD, these results indicate that oligodendrocyte-derived Aβ plays a pivotal role in the early impairment of neuronal circuits in AD, which has important implications for how the disease progresses and is treated. The increased number of oligodendrocytes in human AD brains also raises the intriguing possibility that these cells could potentially offset reduced Aβ production due to neuronal loss as the disease progresses. Challenging Existing Alzheimer’s Theories The authors add, “Our study challenges the long-held belief that neurons are the exclusive source of amyloid beta in the brain, one of the key toxic proteins that builds up in Alzheimer’s Disease. In fact, we show that oligodendrocytes, the myelinating cells of the central nervous system, can also produce significant amounts of amyloid beta which impairs neuronal function, and suggests that targeting these cells may be a promising new strategy to treat Alzheimer’s Disease.” Reference: “Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease” by Rikesh M. Rajani, Robert Ellingford, Mariam Hellmuth, Samuel S. Harris, Orjona S. Taso, David Graykowski, Francesca Kar Wey Lam, Charles Arber, Emre Fertan, John S. H. Danial, Matthew Swire, Marcus Lloyd, Tatiana A. Giovannucci, Mathieu Bourdenx, David Klenerman, Robert Vassar, Selina Wray, Carlo Sala Frigerio and Marc Aurel Busche, 23 July 2024, PLOS Biology. DOI: 10.1371/journal.pbio.3002727

DVDV1551RTWW78V